Fenster, Robert J.
Lebois, Lauren A. M.
Ressler, Kerry J.
Suh, Junghyup
Article History
First Online: 27 July 2018
Competing interests
: K.J.R. is on the scientific advisory boards for Resilience Therapeutics, the Sheppard Pratt–Lieber Research Institute, the Laureate Institute for Brain Research, the Army Study to Assess Risk and Resilience in Servicemembers (STARRS) project, the University of California–San Diego VA Center of Excellence for Stress and Mental Health (CESAMH) and the Anxiety and Depression Association of America; provides fee-for-service consultation for Biogen and Resilience Therapeutics; and holds patents for the use ofd-cycloserine and psychotherapy, targeting the pituitary adenylate cyclase-activating polypeptide (PACAP) type 1 receptor for extinction, targeting tachykinin 2 for prevention of fear and targeting angiotensin to improve extinction of fear. R.J.F., L.A.M.L. and J.S. declare no competing interests.